First Light Asset Management LLC Takes $20.27 Million Position in TriSalus Life Sciences, Inc. $TLSI

First Light Asset Management LLC bought a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,066,827 shares of the company’s stock, valued at approximately $20,267,000. TriSalus Life Sciences comprises approximately 1.8% of First Light Asset Management LLC’s investment portfolio, making the stock its 18th biggest position. First Light Asset Management LLC owned 0.08% of TriSalus Life Sciences at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences during the second quarter valued at $47,000. Invesco Ltd. bought a new position in TriSalus Life Sciences in the fourth quarter valued at about $72,000. Abel Hall LLC purchased a new position in TriSalus Life Sciences in the fourth quarter worth about $73,000. Finally, HighMark Wealth Management LLC purchased a new position in TriSalus Life Sciences in the fourth quarter worth about $75,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Stock Performance

Shares of TLSI opened at $4.22 on Monday. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58. The business has a 50-day simple moving average of $3.88 and a two-hundred day simple moving average of $4.38. The stock has a market cap of $259.19 million, a price-to-earnings ratio of -2.99 and a beta of 0.43. TriSalus Life Sciences, Inc. has a 52 week low of $2.20 and a 52 week high of $7.95.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on TLSI. Weiss Ratings cut shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Lake Street Capital cut their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of “Hold” and a consensus price target of $7.50.

Insider Activity

In other news, Director Mats Wahlstrom bought 60,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $2.53 per share, with a total value of $151,800.00. Following the acquisition, the director owned 147,555 shares of the company’s stock, valued at $373,314.15. The trade was a 68.53% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael P. Stansky bought 410,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $2.50 per share, for a total transaction of $1,025,000.00. Following the purchase, the director owned 1,240,722 shares in the company, valued at $3,101,805. This trade represents a 49.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 719,682 shares of company stock valued at $1,804,176 in the last ninety days. Corporate insiders own 16.30% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.